Associate Director, Medical Affairs | Diabetes, Obesity, and CVDs | Physiologist | Powerlifter🏋️♀️🫀🫁🏃🏼♀️
Joined December 2016
- Tweets477
- Following840
- Followers368
- Likes2.8K
Liz Pekas, PhD retweeted
The @TheLancetEndo Commission said: preclinical obesity = risk. Clinical obesity = active disease >> Treat each accordingly. Evidence-based, standard medicine. Not complicated.
Now a @NatureComms study confirms preclinical obesity = risk; it does not show it is disease. Exactly the Commission’s position.
Spinning this as “proof” that the Commission’s framework is confusing and dismissing a legitimate scientific debate held @ObesityCan as “unhelpful”—frankly makes little sense…unless the aim is to foment controversy, for whatever reason.
That is what’s truly unhelpful
Nat Comm paper= risk, not disease. Lancet Commission : preclinical obesity =risk. Risk ≠ disease. Different treatment intensities.
This is confirmation. not contradiction. So why manufacture controversy?@FRubinoMD
Liz Pekas, PhD retweeted
📢 New journal launch
The first article in Diabetes, Obesity, and Cardiometabolic CARE has been published.
📝 "Pharmacologic Treatment of Obesity in Adults: Standards of Care in Overweight and Obesity" presents evidence-based guidance for medication use as part of comprehensive, person-centered obesity care.
🔗 Read more: doi.org/10.2337/doci25-0008
#DOCMCARE #ObesityCare #StandardsOfCare
ALT Flowchart illustrating obesity-related disease management, highlighting lifestyle advice and medication strategies. Emphasizes personalized treatment goals.
Liz Pekas, PhD retweeted
AHA/ACC have released the 2025 High Blood Pressure Guideline, emphasizing prevention and early treatment to reduce cardiovascular disease risk.
Read the Guideline in @HyperAHA & @CircAHA and check out our hub with commentaries and more:
ahajrnls.org/4mlSNs4...
Liz Pekas, PhD retweeted
💡Dr @ArunJSanyalVCU shares insights from the phase 3 ESSENCE trial examining #semaglutide 2.4 mg for metabolic dysfunction-associated #steatohepatitis.
📽️Watch here👉 ow.ly/Z6nY50WoxQL
#MASH #CKM #CVRM #CardioX #CardioEd
Liz Pekas, PhD retweeted
The muscle–adipose–liver axis is critical, yet underrecognized, in #MASLD.
Sarcopenic obesity affects ~50% with #MASLD and drives ⬆️ ASCVD and liver fibrosis.
@ChannapragadaV and I argue it's time to standardize definitions and intervene early:
link.springer.com/article/10…
Liz Pekas, PhD retweeted
🚨 New ADA Consensus Report: A multidisciplinary call to action on NAFLD and MAFLD in people with diabetes. Learn how early detection, screening, and team-based care can change outcomes.
📰 Read now: diabetesjournals.org/care/lo…
#Diabetes #NAFLD #MAFLD
@AmDiabetesAssn @ADA_DiabetesPro @DiabetesCareADA
ALT Figure 6—Impaired awareness of hypoglycemia from risk factors in cirrhosis. CKD, chronic kidney disease. Adapted with permission from Castera and Cusi (19).
ALT An academic article on metabolic dysfunction-associated fatty liver disease (MAFLD) published in the Diabetes Care journal, detailing its prevalence with diabetes and guidelines for screening and intervention.
Liz Pekas, PhD retweeted
Compared to low-volume physical activity, high-volume physical activity is associated with a lower risk of all-cause mortality but similar risk for clinical CAD events. ahajournals.org/doi/epub/10.…
Liz Pekas, PhD retweeted
Happy World Liver Day! The liver is often overlooked in diabetes care.
New guidance from @AmDiabetesAssn is coming soon—stay tuned!
#WorldLiverDay #LiverHealth #DiabetesCare
Liz Pekas, PhD retweeted
🎉 Help us congratulate Dr. Adam Rosen who was selected as the new director of the School of Health & Kinesiology after a national search!
ALT Headshot of Dr. Adam Rosen, Director of the School of Health and Kinesiology
Liz Pekas, PhD retweeted
Intermittent fasting at any time of day is good for losing (some) weight but does not reduce visceral adipose tissue.
nature.com/articles/s41591-0…
Liz Pekas, PhD retweeted
#MASLD Health Tip of the Day:
Enjoy your coffee!
Drinking 3 cups of black coffee daily can reduce liver inflammation and support liver health, and has been linked to lower fibrosis
A little cream or sugar is okay, but black coffee offers the most benefit. ☕ #LiverHealth
Liz Pekas, PhD retweeted
🔥 🆙 to publish this work with @HD3vedi and team regarding the importance of #exercise across all types and stages of steatotic liver disease!
Check it out here:
onlinelibrary.wiley.com/doi/…
Liz Pekas, PhD retweeted
"Our findings suggest that high-intensity resistance exercises are well tolerated by both mother and fetus, including while using the Valsalva manoeuvre." - great study to address a commonly asked clinical question!
Maternal and fetal responses to acute high-intensity resistance exercise during pregnancy 🤰💪
NEW #OriginalResearch in the BJSM ✅
What happens to fetal heartrate during resistance exercise? Does the use of Valsalva effect this?
Exciting new study from @ExercisePreg and team 👏
👉 bit.ly/3DnKzOC
Liz Pekas, PhD retweeted
#PRESS: European regulatory authority adopts positive opinion for an update of Novo Nordisk product label to reflect risk reduction of kidney disease-related events
Liz Pekas, PhD retweeted
What’s new in CGMs? Discover the latest FDA-approved options & OTC CGMs at ADA's member-exclusive webinar!
📅 Dec 17, 2024 | 4–5 PM ET
Expert faculty: Drs. Ahn, Ekhlaspour, Shah, & Welch
Register now: bit.ly/3OFaeEX
#DiabetesCare @Laya_Ekhlaspour @AhnCall @ViralShah_DM
Liz Pekas, PhD retweeted
Compounded GLP 1 and Dual GIP/GLP 1 Receptor Agonists: A Statement from @ADA_DiabetesPro
diabetesjournals.org/care/ar…
Expert guidance lighting up a black out of information @JoshuaNeumiller @RozalinaMD @nuhaaelsayed
A little #liver transplant physiology to distract me on the stairmaster ? Don’t mind if I do!
@APSPhysiology
@APSPublications
